Published in Cancer Weekly, March 18th, 2003
According to a study from Spain, "Weekly paclitaxel was initially used to exploit the radio sensitizing properties of the drug. However, the observed improvement in therapeutic index with this regimen encouraged further use of weekly regimens, with and without radiotherapy, as a single agent or in combination with other regimens. Single agent weekly paclitaxel, at doses ranging from 50-200 mg/m2/week, has been associated with response rates of 23-56% with acceptable toxicity."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.